| Proposed Ticker: IACT | 654 Madison Avenue, Suite 1606 | |
| Exchange: NASDAQ-National Market | New York, New York 10021 | |
| Industry: Manufacturing | (212) 319-3500 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 6/28/96 | |
| U.S. Shares Filed: | 2,000,000 | Filing Range: | $8.00 - $10.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $18,000,000 | |
| Primary Shares: | 2,000,000 | Expenses: | - | |
| Secondary Shares: | 0 | Shs Out After: | 5,182,924 | |
| Manager | Tier | Phone |
| Dakin Securities Corporation | Lead Manager | (415) 981-2114 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/96 | |||
| Revenue: | $0.27 | $0.00 | Assets: | $6.70 | |
| Net Income: | -$5.19 | -$1.50 | Liabilities: | -$1.33 | |
| EPS: | -$1.73 | -$0.48 | Equity: | $8.02 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Interact develops, markets and manufactures products designed to facilitate the effective use of minimally invasive surgical procedures and enhance clinical performance. The Company's initial product, Preview, was launched in June 1996. Preview, provide the clinician with a detailed three-dimensional model of the patient-specific anatomy manufactured by processing computed tomography or magnetic resonance images on the Company's proprietary software platform at its production facility. The Company delivers its Preview models to the clinician embodied in user-friendly proprietary viewing software augment traditional two-dimensional medical imaging tools and allow the clinician, without significant computer expertise, to manipulate information, perform measurement and conduct pre-surgical planning for use primarily in MIS procedures. The Company is also currently also currently field testing a pre-production prototype of GastroSim, and interactive virtual reality simulator for teaching and training clinicians. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for commercialization of products, research and development, clinical testing, repayment of approximately $2.6 million of indebtedness, capital expenditures, working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.